Outcome of Myeloma Patients with COVID-19 on Active Lenalidomide-Based Therapy: Does Lenalidomide Protect From Severe COVID-19?
作者信息
Tailor Imran K, Alshehry Nawal F, Zaidi Syed Z, Marei Mohammed A, Motabi Ibraheem H, Alfayez Mansour, Altaf Syed Y
机构信息
Department of Adult Hematology and Bone Marrow Transplantation, King Fahad Medical City, Riyadh, Saudi Arabia.
出版信息
Hematol Oncol Stem Cell Ther. 2023 Jan 12;16(1):88-90. doi: 10.1016/j.hemonc.2020.08.002.
Abstract
摘要
相似文献
1
Outcome of Myeloma Patients with COVID-19 on Active Lenalidomide-Based Therapy: Does Lenalidomide Protect From Severe COVID-19?接受基于来那度胺的积极治疗的COVID-19骨髓瘤患者的结局：来那度胺能否预防重症COVID-19？
Hematol Oncol Stem Cell Ther. 2023 Jan 12;16(1):88-90. doi: 10.1016/j.hemonc.2020.08.002.
2
Pembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high-risk multiple myeloma.帕博利珠单抗、来那度胺和地塞米松用于高危多发性骨髓瘤患者自体移植后治疗
Am J Hematol. 2021 Nov 1;96(11):E430-E433. doi: 10.1002/ajh.26333. Epub 2021 Sep 17.
3
Successful outcome of anaplastic multiple myeloma with lenalidomide, cyclophosphamide, and dexamethasone therapy.来那度胺、环磷酰胺和地塞米松治疗间变性多发性骨髓瘤取得成功结果。
Ann Hematol. 2021 Dec;100(12):3039-3040. doi: 10.1007/s00277-020-04244-7. Epub 2020 Sep 2.
4
Daratumumab, lenalidomide and dexamethasone in newly diagnosed systemic light chain amyloidosis patients associated with multiple myeloma.达雷妥尤单抗、来那度胺和地塞米松用于新诊断的与多发性骨髓瘤相关的系统性轻链淀粉样变患者
Br J Haematol. 2022 Aug;198(3):e38-e41. doi: 10.1111/bjh.18234. Epub 2022 May 7.
5
[Carfilzomib, lenalidomide, and dexamethasone therapy for refractory and relapsed multiple myeloma: a single-center study of 29 patients].卡非佐米、来那度胺和地塞米松治疗难治性和复发性多发性骨髓瘤：29例患者的单中心研究
Rinsho Ketsueki. 2018;59(6):698-700. doi: 10.11406/rinketsu.59.698.
6
Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study.英地昔单抗瑞妥昔单抗联合来那度胺或泊马度胺治疗复发/难治性多发性骨髓瘤的多中心 1/2a 期研究。
Lancet Haematol. 2021 Nov;8(11):e794-e807. doi: 10.1016/S2352-3026(21)00208-8. Epub 2021 Sep 13.
7
An open-label, pharmacokinetic study of lenalidomide and dexamethasone therapy in previously untreated multiple myeloma (MM) patients with various degrees of renal impairment - validation of official dosing guidelines.一项关于来那度胺联合地塞米松治疗不同程度肾功能损害的初治多发性骨髓瘤（MM）患者的开放性、药代动力学研究 - 官方剂量指南的验证。
Leuk Lymphoma. 2020 Aug;61(8):1860-1868. doi: 10.1080/10428194.2020.1747064. Epub 2020 May 31.
8
Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14).泊马度胺联合低剂量地塞米松诱导治疗来那度胺难治性多发性骨髓瘤（ALLG MM14）后计划停用 dexamethasone 。 （注：原文中 dexamethasone 这个词前面应该是有具体情况说明为何这样用，单纯看这个词在医学领域一般叫地塞米松，这里直接音译成“ dexamethasone ”保留英文，以便符合原文表述情况。）
Haematologica. 2022 Jan 1;107(1):321-325. doi: 10.3324/haematol.2021.278655.
9
A phase II clinical trial of lenalidomide intensification in patients with serologic/asymptomatic progression of multiple myeloma while on lenalidomide maintenance: a tri-state transplant consortium study.来那度胺维持治疗期间血清学/无症状进展的多发性骨髓瘤患者接受来那度胺强化治疗的II期临床试验：一项三州移植联盟研究
Leuk Lymphoma. 2020 Feb;61(2):488-490. doi: 10.1080/10428194.2019.1672058. Epub 2020 Jan 19.
10
Daratumumab, lenalidomide, and dexamethasone combination in relapsed/refractory myeloma patients: a real-life single-center experience.达雷妥尤单抗、来那度胺和地塞米松联合治疗复发/难治性骨髓瘤患者：单中心真实世界经验
Leuk Lymphoma. 2020 Dec;61(13):3255-3258. doi: 10.1080/10428194.2020.1802452. Epub 2020 Aug 10.
引用本文的文献
1
Unsupervised multi-scale clustering of single-cell transcriptomes to identify hierarchical structures of cell subtypes.单细胞转录组的无监督多尺度聚类以识别细胞亚群的层次结构。
Res Sq. 2024 Dec 23:rs.3.rs-5671748. doi: 10.21203/rs.3.rs-5671748/v1.
2
Molecular mechanisms of thalidomide effectiveness on COVID-19 patients explained: ACE2 is a new ΔNp63α target gene.赛洛昔布在 COVID-19 患者中的作用机制得到解释：ACE2 是一个新的 ΔNp63α 靶基因。
J Mol Med (Berl). 2024 Nov;102(11):1371-1380. doi: 10.1007/s00109-024-02485-x. Epub 2024 Sep 18.
3
Can Lenalidomide Protect against Severe COVID-19 Symptoms in Multiple Myeloma Patients? A Case Series and Review of the Literature.来那度胺能否预防多发性骨髓瘤患者出现严重的新冠症状？病例系列及文献综述
Eur J Case Rep Intern Med. 2022 Mar 9;9(3):003216. doi: 10.12890/2022_003216. eCollection 2022.
4
Challenges posed by COVID-19 in cancer patients: A narrative review.COVID-19 对癌症患者带来的挑战：一篇叙述性综述。
Cancer Med. 2022 Feb;11(4):1119-1135. doi: 10.1002/cam4.4519. Epub 2021 Dec 23.
本文引用的文献
1
Cytokine Storms: Understanding COVID-19.细胞因子风暴：了解 COVID-19。
Immunity. 2020 Jul 14;53(1):19-25. doi: 10.1016/j.immuni.2020.06.017. Epub 2020 Jun 28.
2
Determinants of COVID-19 disease severity in patients with cancer.癌症患者 COVID-19 疾病严重程度的决定因素。
Nat Med. 2020 Aug;26(8):1218-1223. doi: 10.1038/s41591-020-0979-0. Epub 2020 Jun 24.
3
Multiple myeloma and COVID-19.多发性骨髓瘤与新型冠状病毒肺炎
Leukemia. 2020 Jul;34(7):1961-1963. doi: 10.1038/s41375-020-0879-9. Epub 2020 Jun 1.
4
Clinical outcome of coronavirus disease 2019 in haemato-oncology patients.血液肿瘤患者中2019冠状病毒病的临床结局
Br J Haematol. 2020 Jul;190(2):e64-e67. doi: 10.1111/bjh.16852. Epub 2020 Jun 10.
5
COVID-19 outcomes in patients with hematologic disease.血液系统疾病患者的新型冠状病毒肺炎结局
Bone Marrow Transplant. 2020 Nov;55(11):2180-2184. doi: 10.1038/s41409-020-0931-4. Epub 2020 May 6.
6
Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review.免疫调节疗法治疗重症 COVID-19。超越抗病毒治疗：全面综述。
Autoimmun Rev. 2020 Jul;19(7):102569. doi: 10.1016/j.autrev.2020.102569. Epub 2020 May 3.
7
Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System.纽约医院系统中 COVID-19 癌症患者的病死率。
Cancer Discov. 2020 Jul;10(7):935-941. doi: 10.1158/2159-8290.CD-20-0516. Epub 2020 May 1.
8
The many faces of the anti-COVID immune response.抗新冠病毒免疫反应的多面性。
J Exp Med. 2020 Jun 1;217(6). doi: 10.1084/jem.20200678.
9
The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients.布鲁顿酪氨酸激酶（BTK）抑制剂依鲁替尼可能对新冠病毒感染患者的肺损伤具有保护作用。
Blood. 2020 May 21;135(21):1912-1915. doi: 10.1182/blood.2020006288.
10
Multiple myeloma: 2020 update on diagnosis, risk-stratification and management.多发性骨髓瘤：2020 年诊断、风险分层和治疗更新。
Am J Hematol. 2020 May;95(5):548-567. doi: 10.1002/ajh.25791.
Zotero 插件